US4927916A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Method of producing fibrin-specific monoclonal antibodies lacking fibrinogen-cross-reactivity using fibrin-specific peptides
Assignee: General Hospital Corp
•
Filing: 1986-01-30
•
Granted: 1990-05-22
•
Expires: 2006-01-30
Abstract
Abstract Peptides comprising fibrin-specific epitopic sequences are used to prepare hybridoma cell lines producing antifibrin-specific monoclonal antibodies substantially devoid of fibrinogen-cross-reactivity obtained by somatic cell fusion. The antibodies are useful for the in vivo and in vitro detection of thrombi and fibrin deposits.
Inventors
- 👤 Gary R. Matsueda
- 👤 Edgar Haber
- 👤 Kwan Hui
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-05 21:12
CPC Classifications
A; A61; A61K; A61K51/00; A61K51/02; A61K51/04; A61K51/08; A61K51/10; A61K51/1018; A61K51/1093; C; C07; C07K; C07K14/00; C07K14/435; C07K14/745; C07K16/00; C07K16/18; A61K2123/00; Y; Y10; Y10S; Y10S530/00; Y10S530/806; Y10S530/807; Y10S530/808; Y10S530/809; Y10S530/81; Y10S530/812
Claims Analysis
Total Claims: 4
Claim 1
Independent Claim
95 words
A process for producing monoclonal anti-fibrin specific antibodies, devoid of cross reactivity with fibrinogen comprising: a. obtaining lymphocytes from a animal immunized against the peptide fragment comprising A-B-C-D-E-F-G attached to a suitable immunogenic carrier, wherein A is glycine; B is histidine or proline; C is arginine; D is proline or valine; E is aspartic acid or glutamic acid; G is lysine or arginine; b. fusing said lymphocytes with a meyloma cell line to produce hydridomas which secrete anti-fibrin specific antibodies substantially devoid of fibrinogen cross-reactivity; c. cultivating said hybridomas; and d. isolating said secreted antibodies.
Claim 2
Dependent Claim
95 words
A process for producing monoclonal anti-fibrin specific antibodies, devoid of cross reactivity with fibrinogen comprising: a. obtaining lymphocytes from a animal immunized against the peptide fragment comprising A-B-C-D-E-F-G attached to a suitable immunogenic carrier, wherein A is glycine; B is histidine or proline; C is arginine; D is proline or valine; E is aspartic acid or glutamic acid; G is lysine or arginine; b. fusing said lymphocytes with a meyloma cell line to produce hydridomas which secrete anti-fibrin specific antibodies substantially devoid of fibrinogen cross-reactivity; c. cultivating said hybridomas; and d. isolating said secreted antibodies.
Claim 3
Dependent Claim
13 words
The process of claim 1, wherein said lymphocytes are comprised of spleen cells.
Claim 4
Dependent Claim
13 words
The process of claim 2, wherein said spleen cells are mice spleen cells.
References Cited (Backward Citations)
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1993-05-21 | 1993-11-20 | 1994-05-22 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1997-05-21 | 1997-11-20 | 1998-05-22 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2001-05-21 | 2001-11-20 | 2002-05-22 | $7700.00 | Window Closed / Lapsed |